Objective— An increased mean platelet volume (MPV), as an indicator of larger, more reactive platelets resulting from an increased platelet turnover, may represent a risk factor for overall vascular mortality, including myocardial infarction. We intended to identify patients at higher risk of dying from vascular disease in a large, hospital-based cohort. Methods and Results— A total of 206 554 first-ever admissions to the Allgemeines Krankenhaus Wien for determination of MPV between January 1996 and July 2003 were included. Primary end points were overall vascular mortality and death due to ischemic heart disease. Multivariate Cox regression adjusted for sex, age, and platelet count was applied for analysis. MPV values were categorized into quintiles, with the lowest quintile serving as the reference category. Compared with individuals with lower MPV (<8.7 fL), hazard ratios for overall vascular mortality gradually increased to 1.5 in the highest category (≥11.01 fL). The relationship of MPV to ischemic heart disease was even stronger and increased from 1.2 (8.71 to 9.60 fL category) to 1.8 in the highest category (≥11.01 fL). Conclusion— Our results indicate that patients with an increased MPV (≥11.01 fL) are at higher risk of death due to ischemic heart disease, with hazard ratios comparable to those reported for obesity or smoking.
Our data support the hypothesis that SCH might represent an independent risk factor for overall and vascular mortality, especially in men below 60 years. Whether this group would benefit from replacement therapy should be evaluated in interventional studies.
The creation of a neovagina using the Wharton-Sheares-George method does not require allogenic or autologous transplants, nor does it require traction devices or specialized surgical equipment. Furthermore, the procedure is comparatively simple to perform and easy to learn. By following our step-by-step description of this technique, surgeons can offer a minimally invasive, quick, and safe surgical option that provides long-term results that are both functionally and anatomically satisfying. We believe that this technique represents a valuable alternative for the creation of a neovagina in patients with MRKH syndrome and thus should be investigated on a broader scale in the future.
1817 Introduction: Identifying patients with optimal response and long survival is important for clinical guidance because patients with these features are likely not to need further therapy. The techniques applied for classifying these patients should be readily available, standardized, and not liable to subjective interpretation. Here we compare the clinical usability of Hevylite™ (HLC) assay, FLC assay, IFE (immunofixation electropheresis), PMPC (bone marrow plasma cell) infiltration and isotype suppression for identifying patients at their best response with long term survival. Methods and Patients: 65 multiple myeloma patients (median age at maximum response 64, range 33–85; 42 IgG, 23 IgA) were enrolled following the minimum assignment of very good partial response using international myeloma working group guidelines. Patients had been enrolled into various clinical trials and been treated with different induction protocols (VAMP, VMCP+IFNa2b, Thal-Dex, MP, VMP). Median follow was 4.5 years, range 0.5–12 years. Heavy/light chain analysis was retrospectively performed for the monoclonal plasma cell immunoglobulin and its isotype matched pair (42 IgGκ / IgGλ and 23 IgAκ / IgAλ) using commercially available immunoassays (Hevylite™, The Binding Site, Birmingham, UK). Isotype matched immunoparesis was recorded if the patients immunoglobulin concentration was 33% below the bottom of the normal range (IgGk, IgGl, IgAk, IgAl), similarly immunoparesis was assessed if the patients total immunoglobulin levels were 33% below the normal range (IgG, IgA, IgM). Results were compared to bone marrow biopsy, serum free light chain (Freelite™, The Binding Site, Birmingham, UK) and standard immunoglobulin assays. Overall survival was estimated by the product limiting method of Kaplan Meier and survival compared using the log rank test, proportional hazards were assessed using the Cox proportional hazard model. Results: Comparison of patients at maximum response with and without IF-positivity, abnormal HLC ratios, abnormal FLC ratios or BMPC infiltration >5% did not reveal significantly different survival rates. Only patients with an abnormal HLC ratio showed a tendency for shorter survival (table 1). When all markers were combined a difference in the 5 year survival rate was noted (50% as compared to 100%), but due to the limited power, the statistical analysis revealed a tendency for reduced survival only. Discrimination of patients according to HLC pair suppression produced a highly significant difference in overall survival with a 5 year survival rate of 43% compared to 70% (figure 1). Median overall survival was 4.8 years vs. 8.5 years (HR, 2.5 CI: 1.1–5.54,p <0.02). In contrast, suppression of the non-involved isotype immunoglobulin (i.e. IgG concentrations in an IgA MM patient) was not found to be associated reduced overall survival (IgG or IgA, p=0.75, IgM, p=0.9) Discussion: These findings show the importance of immunoparesis at time of maximum response. This phenomenon is specific to the non-involved isotype matched immunoglobulin suggesting a preferential isotype specific inhibition mechanism not previously identified. Interestingly, among the other parameters only abnormal heavy light chain ratio showed a tendency for shorter survival. However, when all of the factors were considered together a small population (4/61, 7%) was identified as having an exceptionally long remission (OS, median: 5.9 years (2.0 – 10.2) Conclusion: The non-involved isotype matched pair suppression has previously been shown to be a prognostic factor in MGUS transformation and in predicting progression free survival in MM patients. Here for the first time we identify this marker as being the most important marker in predicting outcome at maximum response. Disclosures: Carr-Smith: Binding Site: Employment. Hughes:Binding Site: Employment. Harding:Binding Site: Employment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.